Phase IIb clinical study evaluating the efficacy and safety of TAR-200 in combination with Cetrelimab, TAR-200 alone, or Cetrelimab alone in participants with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calm
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: JANSSEN-CILAG, SA
- Phase: II
- Execution start: 10/03/2023
- End of execution: 30/03/2027
- IP: IGNACIO PUCHE SANZ